Femasys (NASDAQ:FEMY) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Femasys (NASDAQ:FEMY) issued its quarterly earnings data on Friday. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.02), Zacks reports. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.73 million.

Femasys Price Performance

FEMY opened at $2.29 on Friday. Femasys has a one year low of $2.19 and a one year high of $22.20. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.98 and a current ratio of 3.91. The stock’s fifty day moving average is $3.59 and its 200-day moving average is $7.31. The company has a market capitalization of $6.92 million, a PE ratio of -0.42 and a beta of -2.08.

Analysts Set New Price Targets

Several analysts have weighed in on FEMY shares. Maxim Group cut their target price on Femasys to $10.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings raised Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Finally, Wall Street Zen raised Femasys to a “hold” rating in a report on Saturday, June 13th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $56.67.

Insider Activity

In other Femasys news, CFO Dov Elefant purchased 15,625 shares of the company’s stock in a transaction on Friday, August 7th. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the chief financial officer owned 15,625 shares in the company, valued at $50,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kathy Lee-Sepsick acquired 15,625 shares of Femasys stock in a transaction on Friday, August 7th. The shares were purchased at an average cost of $3.20 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief executive officer directly owned 15,625 shares of the company’s stock, valued at approximately $50,000. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 38,750 shares of company stock valued at $124,000 in the last ninety days. Company insiders own 7.75% of the company’s stock.

Institutional Investors Weigh In On Femasys

Several hedge funds have recently made changes to their positions in FEMY. Kovack Advisors Inc. acquired a new position in Femasys in the 4th quarter worth approximately $27,000. HRT Financial LP acquired a new stake in Femasys during the 4th quarter valued at $30,000. Cetera Investment Advisers acquired a new stake in Femasys during the 4th quarter valued at $36,000. Osaic Holdings Inc. purchased a new stake in shares of Femasys in the second quarter valued at $45,000. Finally, State Street Corp lifted its holdings in shares of Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares in the last quarter. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.